Synageva proposes $80M follow-on

Synageva BioPharma Corp. (NASDAQ:GEVA) proposed to raise up to $80 million in a follow-on underwritten by Morgan Stanley; JPMorgan; and Cowen. Synageva's lead compound is sebelipase alfa (formerly SBC...